newsfilter
← Latest News
GlobeNewswire·

Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200